Indeed, the results of our present work illustrated that the glioma patients harboring IDH mutation or 1p/19q codeletion displayed lower LOXs expressions and better prognosis than those with wild type or 1p/19q non-codeletion. This evidence concerns the gene IDH1 and central nervous system cancer.